The estrogen receptor (ER/ESR1) is expressed in a majority of breast cancers, and drugs that inhibit ER signaling are the cornerstone of breast cancer pharmacotherapy for ER-positive/HER2-negative disease [1]. Here, ESR1 is linked to breast carcinoma.